Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2475

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2475
---
Jonathan Kurtis (Scientific Co-founder), and Dr. Inderjote Kathuria (Chief Strategy Officer) will be responsible for the research, translational
and preclinical efforts leading to filing an IND and moving a product candidate into human clinical trials.

Our
Development Review Committee, or DRC, which is expected to be comprised of Dr. Jonathan Kurtis (Scientific Co-founder), and Inderjote
Kathuria (Chief Strategy Officer) will be responsible for managing all clinical development efforts, including progress monitoring, allocation
of resources, and continuous re-evaluation of a product candidate’s merits.

Both
these committees will work in collaboration with our OAC described previously to ensure that each product candidate that enters our pipeline
as well as existing ones continue to meet the criteria we have outlined above.

Our
Therapeutic Programs

Oncology
Product Candidates for NSCLC and GBM

Our
oncology product candidates for NSCLC and GBM:

    ●
    OCX-253
    anti-Chi3l1 Single-target mAb (NSCLC)

    ●
    OCX-410
    anti-Chi3l1/PD-1 Bi-specific antibody (NSCLC)

    ●
    OCX-909
    anti-Chi3l1/CTLA-4 Bi-specific antibody (GBM)

Our
product candidates in our oncology program are based on a drug target pioneered by Dr. Elias. His research demonstrated that a protein
called chitinase 3-like-1, or Chi3l1, is a key driver of multiple disease pathways in primary and metastatic tumor development demonstrating
an 85-95% reduction in primary and metastatic tumor burden in multiple animal models. Animal models of lung cancer and glioblastoma,
a type of brain cancer, showed that inhibition of Chi3l1 resulted in statistically significant tumor reduction – even more so when
combined with immunotherapies to stimulate the body’s own immune response against cancer. Our oncology development pipeline consists
of: (a) an antibody therapeutic product candidate inhibiting Chi3l1; (b) a bi-specific antibody product candidate inhibiting Chi3l1 plus
PD-1, a checkpoint inhibitor protein; and (c) a bi-specific antibody product candidate inhibiting Chi3l1 plus CTLA-4, another checkpoint
inhibitor protein. These product candidates are targeting non-small cell lung cancer, or NSCLC,